Cancer BiologyCancer ResearchPeer-reviewed
Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer
Stephen L. DeAngelo, Liang Zhao, Sofia Dziechciarz…·Yatrik Madhukar Shah
This study recharacterizes RSL3 as a broad selenoprotein inhibitor, showing its potential as a therapeutic target for colorectal cancer by inducing ferroptosis.
39 citationstop 1%